How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Need help?

Contact us

Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors – Poster Presentation, ESMO 2026

calendar_today October 23, 2026 domain eikon

The post Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors – Poster Presentation, ESMO 2026 appeared first on Eikon Therapeutics .

open_in_new Read original post